Literature DB >> 29972781

The RNA-Binding Protein Scp160p Facilitates Aggregation of Many Endogenous Q/N-Rich Proteins.

Matthew H K Cheng1, Patrick C Hoffmann2, Mirita Franz-Wachtel3, Carola Sparn4, Charlotte Seng5, Boris Maček6, Ralf-Peter Jansen7.   

Abstract

The RNA-binding protein Scp160p is the yeast homolog of the conserved vigilin protein family. These proteins influence a variety of nuclear and cytoplasmic functions. One of Scp160p's reported roles is to increase translation elongation efficiency in a manner related to codon usage. Thus, it can affect translation speed and co-translational folding of nascent peptides. We used polyglutamine (polyQ) reporters to assess Scp160p's effect on protein synthesis and observed that, in the absence of Scp160p, aggregation of polyQ is reduced and toxicity is abolished. We additionally took a proteomic approach and analyzed the impact of Scp160p on the aggregation of endogenous proteins under normal growth conditions. In the absence of Scp160p, aggregation of many Q/N-rich proteins was reduced. Because aggregation mediated by these regions can be important for the proteins' functions, Scp160p may affect many processes via aggregation of Q/N-rich proteins.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SCP160; codon usage; low complexity regions; polyglutamine; protein aggregation; vigilin

Mesh:

Substances:

Year:  2018        PMID: 29972781     DOI: 10.1016/j.celrep.2018.06.015

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  1 in total

1.  HDLBP binds ER-targeted mRNAs by multivalent interactions to promote protein synthesis of transmembrane and secreted proteins.

Authors:  Ulrike Zinnall; Miha Milek; Igor Minia; Carlos H Vieira-Vieira; Simon Müller; Guido Mastrobuoni; Orsalia-Georgia Hazapis; Simone Del Giudice; David Schwefel; Nadine Bley; Franka Voigt; Jeffrey A Chao; Stefan Kempa; Stefan Hüttelmaier; Matthias Selbach; Markus Landthaler
Journal:  Nat Commun       Date:  2022-05-18       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.